Catalyst
Slingshot members are tracking this event:
Shire's (SHPG) CUVITRU Recieves FDA Approval for the Treatment of Primary Immunodeficiency In Over 300 Genetic Disorders
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SHPG |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 14, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Immune Globulin Subcutaneous Solution, Cuvitru, 300 Genetic Disorders
